Price Alert

Mirum Pharmaceuticals Inc... (MIRM)

NASDAQ: MIRM · Real-Time Price · USD

74.18

-0.43 (-0.58%)

At close: Sep 04, 2025, 3:59 PM

75.73

2.09%

Pre-market: Sep 05, 2025, 09:15 AM EDT

-0.58% (1D)

Bid	72
Market Cap	3.73B
Revenue (ttm)	429.16M
Net Income (ttm)	-58.56M
EPS (ttm)	-1.21
PE Ratio (ttm)	-61.31
Forward PE	497.4
Analyst	Buy

Ask	76
Volume	585,314
Avg. Volume (20D)	607,158
Open	74.35
Previous Close	74.61
Day's Range	73.26 - 74.83
52-Week Range	36.86 - 76.02
Beta	0.95

About MIRM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MIRM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MIRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Mirum Pharmaceuticals Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 weeks ago

+12.04%

Mirium Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

4 weeks ago

+2.99%

Mirium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.

News

3 weeks ago · seekingalpha.com

Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum

Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue g...

4 weeks ago · zacks.com

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

4 weeks ago · seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relatio...

4 weeks ago · zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.52 per share a year ago.

4 weeks ago · businesswire.com

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update.

1 month ago · zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.